Vaccine manufacturer employee contracts poliovirus An employee of vaccine manufacturer Bilthoven Biologicals (BBio) has been infected with a poliovirus. The virus was found in a stool sample provided by the employee. The employee concerned is now in isolation.
Limited impact of incorrect data used for list of top 100 ammonia emitters On 1 November 2022, RIVM announced that its list of top-100 ammonia emitters was compiled using incorrect emission factors for some types of livestock housing. RIVM has investigated whether the erroneous data had also been used in other RIVM products.
Annual report ‘Tuberculosis in the Netherlands’ for 2021: slight increase in number of TB patients In 2021, the number of tuberculosis (TB) patients in the Netherlands rose slightly compared to the preceding year: up to 680 TB patients from 622 in 2020. However, the 2021 number was lower than the number for 2019 (754 patients).
Major loss of healthy life years due to long-term complaints after Lyme disease The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.
The number of STI tests keeps increasing The number of clients tested for sexually transmitted infections (STIs) at Dutch STI clinics has increased since 2004.
Antibiotic resistance is stable, however, more resistant bacteria are expected Over recent years, antibiotic resistance to most agents has remained stable in the Netherlands, and the use of antibiotics has slightly decreased.
Improving consumer exposure assessment to chemical substances By combining the available international knowledge, the method to assess the extent to which consumers are exposed to chemical substances via everyday products such as paint, cleaning agents and co
RIVM seeks dialogue with Industry for safe and green chemistry RIVM would like to explore possibilities to eliminate obstacles during innovation of green chemistry with industry.
European research into chemical mixtures launched EU project EuroMix (European Test and Risk Assessment Strategies for Mixtures) was launched recently.
Cost-effective risk assessment of nanomaterials may be feasible Companies, authorities and scientists can save time, money and test animals in the risk assessment of nanomaterials by using available data.